These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22793255)

  • 1. Evaluation of new scaffolds of myeloperoxidase inhibitors by rational design combined with high-throughput virtual screening.
    Aldib I; Soubhye J; Zouaoui Boudjeltia K; Vanhaeverbeek M; Rousseau A; Furtmüller PG; Obinger C; Dufrasne F; Nève J; Van Antwerpen P; Prévost M
    J Med Chem; 2012 Aug; 55(16):7208-18. PubMed ID: 22793255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.
    Aldib I; Gelbcke M; Soubhye J; Prévost M; Furtmüller PG; Obinger C; Elfving B; Alard IC; Roos G; Delporte C; Berger G; Dufour D; Zouaoui Boudjeltia K; Nève J; Dufrasne F; Van Antwerpen P
    Eur J Med Chem; 2016 Nov; 123():746-762. PubMed ID: 27537923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design, synthesis, and pharmacological evaluation of 3-(aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors.
    Soubhye J; Prévost M; Van Antwerpen P; Zouaoui Boudjeltia K; Rousseau A; Furtmüller PG; Obinger C; Vanhaeverbeek M; Ducobu J; Néve J; Gelbcke M; Dufrasne FO
    J Med Chem; 2010 Dec; 53(24):8747-59. PubMed ID: 21090682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
    Soubhye J; Chikh Alard I; Aldib I; Prévost M; Gelbcke M; De Carvalho A; Furtmüller PG; Obinger C; Flemmig J; Tadrent S; Meyer F; Rousseau A; Nève J; Mathieu V; Zouaoui Boudjeltia K; Dufrasne F; Van Antwerpen P
    J Med Chem; 2017 Aug; 60(15):6563-6586. PubMed ID: 28671460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design.
    Jantschko W; Furtmüller PG; Zederbauer M; Neugschwandtner K; Lehner I; Jakopitsch C; Arnhold J; Obinger C
    Biochem Pharmacol; 2005 Apr; 69(8):1149-57. PubMed ID: 15794935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification.
    Van Antwerpen P; Prévost M; Zouaoui-Boudjeltia K; Babar S; Legssyer I; Moreau P; Moguilevsky N; Vanhaeverbeek M; Ducobu J; Nève J; Dufrasne F
    Bioorg Med Chem; 2008 Feb; 16(4):1702-20. PubMed ID: 18063373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the chlorinating activity of myeloperoxidase by tempol: revisiting the kinetics and mechanisms.
    Queiroz RF; Vaz SM; Augusto O
    Biochem J; 2011 Nov; 439(3):423-31. PubMed ID: 21749327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational drug design applied to myeloperoxidase inhibition.
    Van Antwerpen P; Zouaoui Boudjeltia K
    Free Radic Res; 2015 Jun; 49(6):711-20. PubMed ID: 25788127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs: flufenamic acid and its 5-chloro-derivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid.
    Van Antwerpen P; Dufrasne F; Lequeux M; Boudjeltia KZ; Lessgyer I; Babar S; Moreau P; Moguilevsky N; Vanhaeverbeek M; Ducobu J; Nève J
    Eur J Pharmacol; 2007 Sep; 570(1-3):235-43. PubMed ID: 17610876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of myeloperoxidase: evaluation of 2H-indazoles and 1H-indazolones.
    Roth A; Ott S; Farber KM; Palazzo TA; Conrad WE; Haddadin MJ; Tantillo DJ; Cross CE; Eiserich JP; Kurth MJ
    Bioorg Med Chem; 2014 Nov; 22(22):6422-9. PubMed ID: 25438766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavonoids as promoters of the (pseudo-)halogenating activity of lactoperoxidase and myeloperoxidase.
    Gau J; Furtmüller PG; Obinger C; Prévost M; Van Antwerpen P; Arnhold J; Flemmig J
    Free Radic Biol Med; 2016 Aug; 97():307-319. PubMed ID: 27350402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quercetin and its in vivo metabolites inhibit neutrophil-mediated low-density lipoprotein oxidation.
    Loke WM; Proudfoot JM; McKinley AJ; Needs PW; Kroon PA; Hodgson JM; Croft KD
    J Agric Food Chem; 2008 May; 56(10):3609-15. PubMed ID: 18454540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping myeloperoxidase to identify its promiscuity properties using docking and molecular dynamics simulations.
    Ramírez-Durán LA; Rosales-Hernández MC; Hernández-Rodríguez M; Mendieta-Wejebe JE; Trujillo-Ferrara J; Correa-Basurto J
    Curr Pharm Des; 2013; 19(12):2204-15. PubMed ID: 23016839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the mechanism by which tryptophan analogs inhibit human myeloperoxidase.
    Sliskovic I; Abdulhamid I; Sharma M; Abu-Soud HM
    Free Radic Biol Med; 2009 Oct; 47(7):1005-13. PubMed ID: 19596067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Betanin inhibits the myeloperoxidase/nitrite-induced oxidation of human low-density lipoproteins.
    Allegra M; Tesoriere L; Livrea MA
    Free Radic Res; 2007 Mar; 41(3):335-41. PubMed ID: 17364963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic method for assaying the halogenating activity of myeloperoxidase based on reaction of celestine blue B with taurine halogenamines.
    Sokolov AV; Kostevich VA; Kozlov SO; Donskyi IS; Vlasova II; Rudenko AO; Zakharova ET; Vasilyev VB; Panasenko OM
    Free Radic Res; 2015 Jun; 49(6):777-89. PubMed ID: 25790937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The free amino acid tyrosine enhances the chlorinating activity of human myeloperoxidase.
    Vlasova II; Sokolov AV; Arnhold J
    J Inorg Biochem; 2012 Jan; 106(1):76-83. PubMed ID: 22112843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiol-containing molecules interact with the myeloperoxidase/H2O2/chloride system to inhibit LDL oxidation.
    Van Antwerpen P; Boudjeltia KZ; Babar S; Legssyer I; Moreau P; Moguilevsky N; Vanhaeverbeek M; Ducobu J; Nève J
    Biochem Biophys Res Commun; 2005 Nov; 337(1):82-8. PubMed ID: 16171780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors.
    Soubhye J; Aldib I; Elfving B; Gelbcke M; Furtmüller PG; Podrecca M; Conotte R; Colet JM; Rousseau A; Reye F; Sarakbi A; Vanhaeverbeek M; Kauffmann JM; Obinger C; Nève J; Prévost M; Zouaoui Boudjeltia K; Dufrasne F; Van Antwerpen P
    J Med Chem; 2013 May; 56(10):3943-58. PubMed ID: 23581551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid as a substrate and inhibitor of myeloperoxidase: identification of amine adducts and the influence of superoxide dismutase on their formation.
    Forbes LV; Furtmüller PG; Khalilova I; Turner R; Obinger C; Kettle AJ
    Biochem Pharmacol; 2012 Oct; 84(7):949-60. PubMed ID: 22846601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.